Blake Raggio, MD
Plastic Surgery within the Head & Neck · Montgomery, ALNPI 1497174189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 55.5% of the total.
Across 39 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Revance Therapeutics, Inc.$93
- Merz North America, Inc.$65
- Stryker$52
- Sanofi$51
- Merck$35
- plus $140 from 7 others
What the payments were for
- Food & beverage$980100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $544 |
| Revance Therapeutics, Inc. | 2 | $93 |
| Merz North America, Inc. | 3 | $65 |
| Stryker | 3 | $52 |
| Sanofi | 2 | $51 |
| Merck | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Innovation Technologies Inc | 1 | $29 |
| Zimmer Biomet | 1 | $18 |
| Axogen | 1 | $17 |
| Neurent Medical Limited | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $13 |
| Intersect ENT, Inc. | 1 | $13 |
How this compares
Too few plastic surgery within the head & neck providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 115 | $1,780 |
| Ipratropium Bromide | 49 | $1,690 |
| Azelastine Hcl | 33 | $1,153 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 11 | $573 |
| Celecoxib | 41 | $490 |
| Montelukast Sodium | 32 | $486 |
| Ondansetron OdtOndansetron | 29 | $276 |
| Betamethasone Valerate | 18 | $259 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $228 |
| Mupirocin | 21 | $174 |
| Methylprednisolone | 16 | $161 |
| Doxycycline Hyclate | 11 | $144 |
| ValacyclovirValacyclovir Hcl | 18 | $109 |
| Famotidine | 24 | $89 |
| Tramadol Hcl | 26 | $78 |
Paid to pharmacies, not to this prescriber.
Other plastic surgery within the head & neck in Montgomery
- Harishanker JeyarajanBirmingham$150K
- Artemus CoxBirmingham$5K
- Scott AsherDothan$2K
- Beau VandiverMountain Brk$2K
- Susan McCammonBirmingham$482
- Ed McColloughGulf Shores$471
- Glenn PetersBirmingham$132
- Frederick SilverMobile$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.